(Q24245413)

1

object named as

Sarah Appleton

0 references

Robert J Adams

5

object named as

Robert Adams

0 references

author name string

Terry Jones

2

0 references

Toby J Lasserson

4

0 references

Brian Smith

6

0 references

Julia Muhammed

Cochrane Database of Systematic Reviews

7

0 references

publication date

19 July 2006

0 references

published in

0 references

cites work

Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006101

Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006101

Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006101

An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006101

Assessment of the clinical usefulness of nebulised ipratropium bromide in patients with chronic airflow limitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006101

Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006101

The effect of aerosol ipratropium bromide and salbutamol on exercise tolerance in chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006101

Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006101

Long-acting beta2-agonists for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006101

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006101

Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006101

Bronchodilator reversibility testing in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006101

In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium : a 3-week, randomized, double-blind, within-patient, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006101

Recommendations for the management of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006101

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006101

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006101

Acute bronchodilator trials in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006101

Assessment of bronchodilator efficacy in symptomatic COPD: is spirometry useful?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006101

National and international guidelines for COPD: the need for evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006101

Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006101

Impact of preventing exacerbations on deterioration of health status in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006101

Long-term Treatment Benefits With Tiotropium in COPD Patients With and Without Short-term Bronchodilator Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006101

Influence of age on response to ipratropium and salbutamol in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006101

Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006101

Comparison of a B2 adrenergic agonist and an anticholinergic agent given by sequential inhalation in patients with severe chronic obstructive pulmonary disease

21 January 2018

1 reference

12 December 2020

Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease

1 reference

12 December 2020

Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium

1 reference

12 December 2020

[Long-term atrovent treatment of chronic obstructive bronchitis]

1 reference

12 December 2020

A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease

1 reference

12 December 2020

Tiotropium for stable chronic obstructive pulmonary disease

1 reference

12 December 2020

A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease

1 reference

12 December 2020

Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease

1 reference

12 December 2020

Use of Ipratropium Bromide in Patients with Severe Airways Obstruction

1 reference

12 December 2020

Comparison by double-blind study of the combination of an aerosol of salbutamol and ipratropium bromide and its individual effect in chronic bronchitis and bronchial asthma

1 reference

12 December 2020

An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)

1 reference

12 December 2020

Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease

1 reference

12 December 2020

Nebulised ipratropium bromide and salbutamol in chronic bronchitis

1 reference

12 December 2020

Effects of 40 µg AND 400 µ of Ipratropium Bromide in Obstructive Lung Disease

1 reference

12 December 2020

A comparison of effects of inhaling a combined preparation of fenoterol with ipratropium bromide (Duovent) with those of fenoterol and salbutamol

1 reference

12 December 2020

Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysiologic mechanisms

1 reference

12 December 2020

Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care

1 reference

12 December 2020

[Long-term atrovent treatment of chronic obstructive bronchitis]

1 reference

12 December 2020

The action of a tropic acid ester on bronchospasm: a double-blind study (author's transl)

1 reference

12 December 2020

BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS

1 reference

12 December 2020

Efficacy of salmeterol xinafoate in the treatment of COPD

1 reference

12 December 2020

[Comparison of bronchodilator effects and site of action of fenoterol and ipratropium in chronic obstructive bronchitis]

1 reference

12 December 2020

Bronchodilator response in chronic obstructive pulmonary disease.

1 reference

12 December 2020

A comparison of bronchodilating drugs in the treatment of stable COPD

1 reference

12 December 2020

[Experience in long-term use of berodual in the treatment of patients with chronic obstructive bronchitis]

1 reference

12 December 2020

Inhaled antimuscarinic agents and COPD

1 reference

12 December 2020

Is an anticholinergic agent superior to a beta 2-agonist in improving dyspnea and exercise limitation in COPD?

1 reference

12 December 2020

[Clinical comparison of Atrovent and a placebo in patients with chronic obstructive lung diseases]

1 reference

12 December 2020

Prognosis in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006101

7 January 2021